Skip to main content
. Author manuscript; available in PMC: 2014 Feb 14.
Published in final edited form as: J Med Chem. 2013 Jan 30;56(3):1007–1022. doi: 10.1021/jm301485d

Figure 1.

Figure 1

A. Structures of VK1, VK2, and VK3. VK3 is a pro-vitamin, and UBIAD1 converts VK3 or cleaved VK1 into VK2 in situ through geranylgeranylation. Defects in UBIAD1 have been shown to be a dominant enhancer of Parkinson’s related PINK1 mutations. B. Experimental flow. Synthetic approach and selective criteria used to generate more potent and non-toxic VK analogs.